Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01845584

Enrollment

Registered

2013-05-03

Start date

2013-05-31

Completion date

2015-08-31

Last updated

2017-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis Optica Spectrum Disorder

Keywords

IVIG in Neuromyelitis Optica spectrum disorder, Patients with Neuromyelitis Optica spectrum disorder

Brief summary

Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive steroid plus therapy （1g/day for five consecutive days）. Subsequently, patients who not provided adequate effect of therapy to steroids plus therapy will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluated Quantification of nerve and spinal cord impairment （QOSI） and the Expanded Disability Status Scale （EDSS）/ Functional Systems （FS） and anti-aquaporin 4 antibody et al. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.

Interventions

DRUGNPB-01

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients who become positive for anti-aquaporin 4 antibody or have becomed. 2. Patients who have developed myelitis. 3. Patients who run beyond greater than 30 days at least from last time in relapse. 4. Patients who new neurological symptom or worsening neurological symptom or flared neurological symptom have sustained 24 hours at least not associated fever or infection. 5. Patients who have an acute exacerbation at informed consent. 6. Patients who need steroid plus therapy（1g/day for five consecutive days）. 7. Patients who can start steroid plus therapy within 3 days after informed consent. 8. Patients who be inadequate to effect to steroid plus therapy. 9. Patients with greater than or equal to twenty years old at informed consent.

Exclusion criteria

1. Patients who have developed optic neuritis. 2. Patients treated with intravenous immunoglobulin within 14 days before informed consent. 3. Patients with malignancy at informed consent. 4. Patients with history of shock or hypersensitivity for NPB-01. 5. Patients with IgA deficiency. 6. Patients with impaired liver function. 7. Patients with impaired renal function. 8. Patients with cerebro- or cardiovascular disorders. 9. Patients with high risk of thromboembolism. 10. Patients with hemolytic/hemorrhagic anemia. 11. Patients with decreased cardiac function. 12. Patients with decreased platelet.

Design outcomes

Primary

Measure	Time frame
Change from Baseline Quantification of nerve and spinal cord impairment （QOSI） at 29 days	29 days
Change from Baseline Expanded Disability Status Scale （EDSS）/ Functional Systems （FS） at 29 days	29 days
Change from Baseline anti-aquaporin 4 antibody at 29 days	29 days

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026